Zoledronovy kislota-Vista EXPERT konts. for solution for inf. 4mg/5ml fl. 5 ml No. 1

Zoledronovy Kislota-Vista the EXPERT is applied

• to prevention of the symptoms connected with damage of a bone tissue (pathological changes, a compression of a spine column, a complication after surgical interventions and radiation therapy or the hypercalcemia caused by a malignant tumor), at patients with malignant new growths at late stages;
• for treatment of the hypercalcemia caused by a malignant tumor.

Structure

• active ingredient: zoledronic acid;
4 mg of zoledronovy acid anhydrous contain
• 5 ml of a concentrate that corresponds to 4.264 mg of zoledronovy acid of monohydrate;
0.8529 mg of zoledronovy acid anhydrous contain
• 1 ml of a concentrate (in the form of zoledronovy acid of monohydrate);
• other components: a mannitol (E 421), sodium citrate a dihydrate, water for injections.

Contraindication

Hypersensitivity to active ingredient (zoledronovy acid), other bisfosfonata or any of medicine excipients.

Pregnancy or period of feeding by a breast.

Side reactions

Within three days after use of Zoledronovaya Kislota-Vista EXPERT medicine it was usually reported about gostrofazny reactions which symptoms included an ostealgia, fever, weakness, an arthralgia, myalgia, a fever and arthritises with hypostases of joints. These symptoms usually disappear within several days.

At use "Zoledronova kisloty-Vista the EXPERT" revealed the following significant side reactions: disturbance of renal function, jaw necrosis, gostrofazny reactions, hypocalcemia, disorder of vision, fibrillation of auricles, anaphylaxis, interstitial pulmonary disease. Information on the frequency of undesirable reactions at use of medicine in a dose of 4 mg is based mainly on the data obtained at long therapy. The undesirable reactions connected with use "Zoledronova kisloty-Vista the EXPERT" are similar to about what it was reported at use of other bisfosfonat, and can develop approximately at one third of all patients.

Medical means only the doctors having experience of intravenous administration of bisfosfonat have to enter

.

with

Before introduction of 5 ml of a concentrate "Zoledronova kisloty-Vista the EXPERT", containing 4 mg of zoledronovy acid, dissolve 0.9% of solution of sodium chloride or 5% of solution of glucose in 100 ml. Ready solution "Zoledronova kisloty-Vist the EXPERT" for infusions is entered in the form of single intravenous infusion within at least 15 min.

Concentrate "Zoledronova kisloty-Vista the EXPERT" it is impossible to mix with solutions for infusions, calciferous or other bivalent cations, such as lactat Ringera solution, and it is necessary to enter in the form of single intravenous infusion with use of a separate infusional system.

to

Use during pregnancy or feeding by a breast

Medicine is contraindicated to

Feature of use

by

.

Ability to influence speed of response at control of motor transport or other mechanisms

Side reactions of medicine, such as dizziness and drowsiness, can affect ability to run motor transport or to work with other mechanisms therefore the care at control of motor transport or work with difficult mechanisms during use is necessary "Zoledronova kisloty-Vista the EXPERT".

Overdose

Symptoms. Clinical experience of therapy of acute overdose of zoledronovy acid is limited. It was reported about wrong use of zoledronovy acid in a dose of 48 mg.

Treatment. Patients to whom applied the medicament dose exceeding recommended have to be under constant control as there can be a renal failure (including a renal failure), change of electrolytic composition of serum (including concentration of calcium, phosphates and magnesium). At emergence of a hypocalcemia performing infusion of a gluconate of calcium on clinical indicators is recommended. Symptomatic treatment.

during clinical trials along with Zoledronovaya Kislota-Vista EXPERT medicine often appointed by

other medicines: antineoplastic medicines, antibiotics, analgetics. No clinically important interactions were noted. According to the data obtained in the course of the researches in vitro, zoledronovy acid significantly does not contact proteins of blood plasma and does not inhibit enzymes of a system of P450 cytochrome. However special clinical trials on studying medicinal interaction were not conducted.

Is recommended to be careful at simultaneous use of bisfosfonat and aminoglycosides as they can make additive impact therefore calcium level in blood serum can remain reduced longer, than it is necessary. It is recommended to be careful at simultaneous use of bisfosfonat and loopback diuretics as they can make additive impact therefore there can be a hypocalcemia. It is necessary to be careful, appointing "Zoledronovuyu kislotu-Vist AS", etc.

shi potentially nephrotoxic medicines. It is also necessary to mean a possibility of development of a hypomagnesiemia during treatment at patients with a multiple myeloma at introduction of bisfosfonat to combinations with thalidomide the risk of developing a renal failure increases. It was reported about a jaw osteonecrosis at the patients receiving simultaneous treatment "Zoledronova kislotoy-Vista the EXPERT" and antiangiogenic medicines (reduce blood supply of a tumor).

Storage conditions

does not demand special storage conditions. To store out of children's reach.